A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Inclusion Criteria:

- Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the
time of informed consent.

- Have severe or very severe AA, as determined by all of the following:

- Current AA episode of more than 6 months' duration and hair loss encompassing
≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and
baseline.

- No spontaneous improvement over the past 6 months.

- Current episode of severe or very severe AA of less than 8 years. Note:
participants who have severe or very severe AA for ≥8 years may be enrolled if
episodes of regrowth, spontaneous or under treatment, have been observed on the
affected areas over the past 8 years.

- Male or nonpregnant, nonbreastfeeding female participants.

Exclusion Criteria:

- Primarily "diffuse" type of AA.

- Are currently experiencing other forms of alopecia or any other concomitant conditions
that would interfere with evaluations of the effect of study medication on AA.

- Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate
response (for example, absence of significant terminal hair growth after at least 12
weeks of treatment).